MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
0.9736
+0.0131
+1.36%
Opening 15:27 01/02 EST
OPEN
0.9793
PREV CLOSE
0.9605
HIGH
1.040
LOW
0.9500
VOLUME
3.90M
TURNOVER
--
52 WEEK HIGH
5.48
52 WEEK LOW
0.9100
MARKET CAP
182.33M
P/E (TTM)
-4.4114
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HUMA last week (1222-1226)?
Weekly Report · 12/29/2025 10:15
Analysts’ Top Healthcare Picks: Schrodinger (SDGR), Humacyte (HUMA)
TipRanks · 12/22/2025 19:20
Humacyte Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/22/2025 15:09
Humacyte Price Target Maintained With a $25.00/Share by D. Boral Capital
Dow Jones · 12/22/2025 15:09
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
Benzinga · 12/22/2025 14:59
Humacyte announces long-term safety, efficacy results of Symvess
TipRanks · 12/22/2025 13:11
Humacyte Publishes Long-Term Data Assessing Durability Of Symvess In Extremity Arterial Trauma Patients In Journal Of Vascular Surgery Cases, Innovations And Techniques
Benzinga · 12/22/2025 13:04
Humacyte Reports Long-Term Success of Symvess in Extremity Trauma Repair
Reuters · 12/22/2025 13:03
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.